Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabine and LBH 589 in Patients With Triple Negative Metastatic Breast Cancer.

Trial Profile

Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabine and LBH 589 in Patients With Triple Negative Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2014

At a glance

  • Drugs Decitabine (Primary) ; Panobinostat (Primary) ; Tamoxifen
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Sep 2014 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.
    • 06 Oct 2011 Planned end date changed from 1 Nov 2012 to 1 Jul 2016 as reported by ClinicalTrials.gov.
    • 06 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top